Eli Lilly and Co (NYSE:LLY) SVP Susan Mahony sold 5,165 shares of the firm’s stock in a transaction on Friday, April 13th. The shares were sold at an average price of $80.14, for a total transaction of $413,923.10. Following the sale, the senior vice president now owns 45,652 shares in the company, valued at approximately $3,658,551.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Susan Mahony also recently made the following trade(s):
- On Monday, April 16th, Susan Mahony sold 22,544 shares of Eli Lilly and stock. The shares were sold at an average price of $80.09, for a total transaction of $1,805,548.96.
Shares of NYSE:LLY opened at $79.75 on Friday. The firm has a market capitalization of $87,560.18, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 1.46 and a beta of 0.26. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 EPS. equities analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
LLY has been the topic of several research reports. Jefferies Group set a $93.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Goldman Sachs cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price objective for the company from $86.98 to $95.00 in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research report on Tuesday, April 3rd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Bank of America lowered their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Buy” and a consensus target price of $93.16.
A number of institutional investors have recently made changes to their positions in the business. Waldron LP grew its holdings in Eli Lilly and by 15.5% in the 4th quarter. Waldron LP now owns 4,463 shares of the company’s stock worth $376,000 after acquiring an additional 600 shares during the last quarter. East Coast Asset Management LLC. grew its holdings in Eli Lilly and by 22.2% in the 3rd quarter. East Coast Asset Management LLC. now owns 3,360 shares of the company’s stock worth $287,000 after acquiring an additional 610 shares during the last quarter. Clear Investment Research LLC grew its holdings in Eli Lilly and by 23.2% in the 4th quarter. Clear Investment Research LLC now owns 3,247 shares of the company’s stock worth $274,000 after acquiring an additional 611 shares during the last quarter. Tompkins Financial Corp grew its holdings in Eli Lilly and by 1.8% in the 4th quarter. Tompkins Financial Corp now owns 35,604 shares of the company’s stock worth $3,007,000 after acquiring an additional 613 shares during the last quarter. Finally, Harbour Capital Advisors LLC grew its holdings in Eli Lilly and by 2.8% in the 4th quarter. Harbour Capital Advisors LLC now owns 22,673 shares of the company’s stock worth $1,915,000 after acquiring an additional 622 shares during the last quarter. 77.66% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co (LLY) SVP Sells $413,923.10 in Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/20/eli-lilly-and-co-lly-svp-sells-413923-10-in-stock.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.